Real-World Studies
Salvage ASCT linked to durable disease control in relapsed myeloma cohort
Korkmaz et alJournal of Clinical Medicine
In the evolving therapeutic landscape for relapsed/refractory multiple myeloma (R/R MM), salvage autologous stem cell transplantation (ASCT) remains under evaluation alongside newer immunotherapies. A retrospective single-center study analyzed long-term outcomes in 57 patients with R/R MM who underwent salvage ASCT between and . The mean age of the cohort at the time of salvage transplantation was 60.2 ± 8.2 years.
Salvage ASCT was associated with marked deepening of hematologic response: while 50.9% of patients achieved a complete response (CR) or very good partial response (VGPR) prior to the procedure, this proportion rose to 80.7% by day +100 post-transplant. Survival outcomes were durable, showing a median progression-free survival (PFS) of 34.0 months (95% CI, 28.8–39.2) and a median overall survival (OS) of 67.2 months (95% CI, 46.2–88.2) following salvage ASCT. Median OS measured from initial diagnosis reached 130.5 months.
Regarding procedural safety, transplant-related mortality was 3.5%, though infection or febrile neutropenia represented a frequent adverse event, occurring in 77.2% of patients. Multivariate analysis identified elevated lactate dehydrogenase (LDH) levels and pre-transplant refractory status as independent adverse prognostic factors for PFS. In contrast, patient age at salvage ASCT and elevated beta-2 microglobulin levels independently correlated with worse OS. The authors concluded that salvage ASCT provides durable disease control with acceptable procedural mortality in carefully selected patients, noting that prospective trials are needed to define its role relative to novel immunotherapies.
Key Takeaways
- Salvage autologous stem cell transplantation deepened disease control, increasing the complete response or very good partial response rate from 50.9% pre-transplant to 80.7% by day +100, with a median progression-free survival of 34.0 months (95% CI, 28.8–39.2) and a median overall survival of 67.2 months (95% CI, 46.2–88.2).
- Transplant-related mortality was 3.5%, whereas infectious complications or febrile neutropenia occurred in 77.2% of patients.
- Multivariate analysis revealed that elevated LDH and pre-transplant refractory disease were independent predictors of poorer progression-free survival, while age at salvage transplantation and beta-2 microglobulin levels were independently associated with overall survival.
Read the original sourceJournal of Clinical Medicine
